The growth hormone deficiency (GHD) treatment market has made some notable strides on the back of the growing role of GH replacement therapy in managing GHD in adults. Advances in understanding clinical syndrome of GHD and understanding of diagnosis are key trends boosting the GHD treatment market. Clinical practices pertaining to pharmacological management of the syndrome in the GHD treatment market have made remarkable strides in the past five years. A growing body of epidemiological studies have focused on improving the safety, efficacy, and tolerability of GHD, especially in adults. Over the years, numerous benefits of GH replacement therapy have been recognized in mitigating the symptoms or reversing the conditions of this hormonal deficiency. Carniopharyngioma and pituitary adenoma are considered as the most potential causes of adult GHD per some international pharmaco-epidemiological surveillance database.
Some of the benefits of GH replacement therapy are positive impact on body composition, improvement in bone structure, some notable progress in health-related quality of life, and improvement in neuropsychiatric-cognitive, skeletal, and cardiovascular risk factors. Growing number of patients with chronic and severe GH deficiency who are made to undergo GH replacement therapy is a key trend underpinning the evolution of the GHD market.
Are you a start-up willing to tailored insights that will help you align operational and strategic goals in growth journey? Grab an exclusive PDF Brochure for this report!
Growing understanding of prevalence and incidence of adult-onset GH deficiency is a key trend boosting the GHD treatment market. Though exact prevalence are difficult to identify, but per a report by NCBI is ~2-3:10,000 population. In this regard, incidence of adult-onset GHD is a prominent factor. Growing number of studies in aetiology of hypopituitarism has expanded the avenue in the market.
The growing traction of GH hormone receptor polymorphism in the market has paved way to several new revenue streams for the healthcare and life sciences industries. However, childhood-onset isolated GH deficiency and chronic GHD pose considerable challenge for researchers looking to expand the avenue of GHD treatment market, as some studies have shed light on long-term effects on GH replacement therapy. A new avenue in the market has been opened by promise shown by pegylated human growth hormone. The growing mortality associated with hypopituitarism is a key trend boosting the demand for GHD treatment. Progress made in cardiovascular risk markers is also boosting the market.
Companies are focused on developing GH dosing profile that are convenient to patient population. Focus is on developing high safety and tolerability in long-acting GH, especially for GHD in adults. Initial studies abound that pointed to risk of neoplasia in GHD. However, recent studies have pointed otherwise. Companies such as Pfizer revealed encouraging results. Moreover, prolonged-release GH is acting as a new avenue in the GHD treatment market. Aspiring players have conducted research on clinical presentations of GHD to document the benefits of adult GHD. Top players are leaning on expanding their product portfolio in recombinant human growth hormones. Some are focused on developing database in long-term GH replacement to consolidate their positions in the GHD treatment market.
Do you want to assess potential implications of COVID-19 pandemic on your business and boost your agility? Grab an exclusive Sample for this report!
On the regional front, North America and Europe are lucrative markets. Extensive research in clinical management of adult GHD has fueled opportunity generation in North America market. In recent years, GH replacement therapy has considerably changed the course of GHD treatment in Europe and North America. Asia Pacific is expected to be a promising regional market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Get a free copy if the report you purchased is updated within 90 days